Spots Global Cancer Trial Database for isatuximab
Every month we try and update this database with for isatuximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | NCT05873205 | Blood Cancer Refractory Immu... | Isatuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | NCT05873205 | Blood Cancer Refractory Immu... | Isatuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | NCT03104842 | Multiple Myelom... | Isatuximab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| MInimal Residual Disease Adapted Strategy | NCT04934475 | Multiple Myelom... | Isatuximab ASCT | 18 Years - 66 Years | Intergroupe Francophone du Myelome | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi | |
| Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma | NCT05344833 | Multiple Myelom... | Isatuximab Lenalidomide | 18 Years - | University of Illinois at Chicago | |
| Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | NCT04751877 | Multiple Myelom... Myeloma | Isatuximab Lenalidomide Bortezomib Dexamethasone | 65 Years - 79 Years | Poitiers University Hospital | |
| Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | NCT04653246 | Multiple Myelom... Newly Diagnosed... Autologous Stem... | Isatuximab Lenalidomide Bortezomib Inje... Dexamethasone | 75 Years - | Dana-Farber Cancer Institute | |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | NCT06216158 | Multiple Myelom... | Iberdomide Isatuximab Dexamethasone | 18 Years - | University of Heidelberg Medical Center | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | NCT03555149 | Colorectal Canc... | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab Idasanutlin AB928 LOAd703 | 18 Years - | Hoffmann-La Roche | |
| Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma | NCT05344833 | Multiple Myelom... | Isatuximab Lenalidomide | 18 Years - | University of Illinois at Chicago | |
| Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | NCT04653246 | Multiple Myelom... Newly Diagnosed... Autologous Stem... | Isatuximab Lenalidomide Bortezomib Inje... Dexamethasone | 75 Years - | Dana-Farber Cancer Institute | |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | NCT04558931 | Multiple Myelom... | CellProtect Isatuximab | 18 Years - | Karolinska Institutet | |
| Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma | NCT05123131 | Multiple Myelom... | Isatuximab Bortezomib Lenalidomide Dexamethasone (... | 18 Years - 75 Years | Cancer Trials Ireland | |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | NCT05147493 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Bortezomib Cyclophosphamid... Dexamethasone Lenalidomide | 18 Years - | Hellenic Society of Hematology | |
| Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | NCT05145400 | Multiple Myelom... Cancer | Isatuximab Lenalidomide Dexamethasone | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) | NCT04483739 | Multiple Myelom... | Carfilzomib Len... Isatuximab Carf... | 18 Years - 70 Years | Stichting European Myeloma Network | |
| A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | NCT03530683 | Lymphoma Multiple Myelom... Acute Myeloid L... Diffuse Large B... | Maplirpacept (P... Azacitidine Venetoclax Carfilzomib Dexamethasone Anti-CD20 Targe... Isatuximab | 18 Years - | Pfizer | |
| A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | NCT04786028 | Multiple Myelom... | Isatuximab | 18 Years - | Canadian Myeloma Research Group | |
| Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis | NCT04754945 | AL Amyloidosis | Bortezomib Cyclophosphamid... Dexamethasone Isatuximab | 18 Years - | Emory University | |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | NCT05298683 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Pomalidomide Dexamethasone Acetaminophen (... Ranitidine (or ... Diphenhydramine... | 18 Years - | Hellenic Society of Hematology | |
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis | NCT03499808 | Amorphous, Eosi... Constipation Diarrhea Early Satiety Gastrointestina... Hepatomegaly Lymphadenopathy Macroglossia Nausea Primary Systemi... Purpura Recurrent Prima... Refractory Prim... | Isatuximab Laboratory Biom... | 18 Years - | SWOG Cancer Research Network | |
| Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | NCT05346809 | Lymphoma Multiple Myelom... Non-Hodgkin Lym... Relapsed Hodgki... | Isatuximab Standard Proced... | 18 Years - | Columbia University | |
| Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | NCT04083898 | Multiple Myelom... | Isatuximab Bendamustine Prednisone | 18 Years - | Washington University School of Medicine | |
| Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients | NCT05272826 | Multiple Myelom... | Iberdomide Bortezomib Dexamethasone Isatuximab | 65 Years - | Canadian Myeloma Research Group | |
| KRDI in Transplant-Eligible MM | NCT04430894 | Multiple Myelom... | Carfilzomib Isatuximab Lenalidomide Dexamethasone | 18 Years - | Massachusetts General Hospital | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | NCT03555149 | Colorectal Canc... | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab Idasanutlin AB928 LOAd703 | 18 Years - | Hoffmann-La Roche | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT04850599 | Recurrent Plasm... Refractory Plas... | Carfilzomib Isatuximab Pomalidomide | 18 Years - | OHSU Knight Cancer Institute | |
| Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | NCT03617731 | Multiple Myelom... | Lenalidomide Bortezomib Dexamethasone Isatuximab | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| MInimal Residual Disease Adapted Strategy | NCT04934475 | Multiple Myelom... | Isatuximab ASCT | 18 Years - 66 Years | Intergroupe Francophone du Myelome | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| MInimal Residual Disease Adapted Strategy | NCT04934475 | Multiple Myelom... | Isatuximab ASCT | 18 Years - 66 Years | Intergroupe Francophone du Myelome | |
| Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | NCT04912427 | Multiple Myelom... | Isatuximab Bortezomib Dexamethasone | 18 Years - | Washington University School of Medicine | |
| Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy | NCT05066607 | AL Amyloidosis | Isatuximab | 18 Years - | Intergroupe Francophone du Myelome | |
| Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab | NCT05053607 | Multiple Myelom... Refractory Mult... | Digital Health ... Fitbit | 18 Years - | Pack Health | |
| Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | NCT03104842 | Multiple Myelom... | Isatuximab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | NCT02514668 | Plasma Cell Mye... | Isatuximab | 18 Years - | Sanofi | |
| Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients | NCT02990338 | Plasma Cell Mye... | Isatuximab Pomalidomide Dexamethasone | 18 Years - | Sanofi | |
| Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) | NCT04483739 | Multiple Myelom... | Carfilzomib Len... Isatuximab Carf... | 18 Years - 70 Years | Stichting European Myeloma Network | |
| Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | NCT02332850 | Multiple Myelom... | Isatuximab Carfilzomib Dexamethasone | 18 Years - | University of California, San Francisco | |
| Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma | NCT05889221 | Multiple Myelom... Myeloma Multipl... Myeloma | Drug and medica... | 65 Years - | Poitiers University Hospital | |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
